PMID- 28222460
OWN - NLM
STAT- MEDLINE
DCOM- 20170605
LR  - 20181203
IS  - 1533-7294 (Electronic)
IS  - 0094-3509 (Linking)
VI  - 66
IP  - 2 Suppl
DP  - 2017 Feb
TI  - Elements for Success in Managing Type 2 Diabetes With SGLT-2 Inhibitors: Overview 
      of the Efficacy and Safety of SGLT-2 Inhibitors in Type 2 Diabetes Mellitus.
PG  - S5-S12
AB  - Since the approval of the first sodium-glucose cotransporter-2 (SGLT-2) inhibitor 
      by the US Food and Drug Administration (FDA) in 2013, the SGLT-2 inhibitors have 
      assumed key roles in the management of patients with type 2 diabetes mellitus 
      (T2DM). This review covers the safety and efficacy of these agents when used in 
      this patient population.
FAU - Miller, Eden M
AU  - Miller EM
AD  - Executive Director and Co-founder, Diabetes Nation, High Lakes Health Care, St. 
      Charles Hospital, Bend, OR, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Blood Glucose/*drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - *Drug Monitoring
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Kidney/*drug effects
MH  - Male
MH  - Middle Aged
MH  - Risk Assessment
MH  - Sodium-Glucose Transporter 2/*therapeutic use
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - United States
EDAT- 2017/02/22 06:00
MHDA- 2017/06/06 06:00
CRDT- 2017/02/22 06:00
PHST- 2017/02/22 06:00 [entrez]
PHST- 2017/02/22 06:00 [pubmed]
PHST- 2017/06/06 06:00 [medline]
AID - jfp_6602k [pii]
PST - ppublish
SO  - J Fam Pract. 2017 Feb;66(2 Suppl):S5-S12.